These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

99 related items for PubMed ID: 42483

  • 1. Beta-adrenoceptor-blocking agents: pharmacokinetic differences and their clinical implications illustrated on pindolol.
    Meier J.
    Cardiology; 1979; 64 Suppl 1():1-13. PubMed ID: 42483
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Pharmacokinetic comparison of pindolol with other beta-adrenoceptor-blocking agents.
    Meier J.
    Am Heart J; 1982 Aug; 104(2 Pt 2):364-73. PubMed ID: 6125095
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics and pharmacodynamics of mepindolol sulphate.
    Bonelli J, Hitzenberger G, Krause W, Wendt H, Speck U.
    Int J Clin Pharmacol Ther Toxicol; 1980 Apr; 18(4):169-76. PubMed ID: 6103882
    [Abstract] [Full Text] [Related]

  • 6. [Hepatic clearance of drugs in kidney failure].
    Balant L.
    Nephrologie; 1983 Apr; 4(2):45-7. PubMed ID: 6136004
    [No Abstract] [Full Text] [Related]

  • 7. [Pharmacological basis for the therapy of cardiovascular disease with beta-adrenoceptor blocking drugs (author's transl)].
    Lemmer B.
    Herz; 1982 Jun; 7(3):168-78. PubMed ID: 6124492
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The pharmacokinetic properties of beta adrenoceptor blocking drugs.
    Gugler R.
    Arch Int Pharmacodyn Ther; 1980 Jun; Suppl():27-31. PubMed ID: 6106455
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. beta-Adrenoceptor blocking effects and pharmacokinetics of pindolol. A study in hypertensive Africans.
    Salako LA, Falase AO, Ragon A, Adio RA.
    Eur J Clin Pharmacol; 1979 Jun 12; 15(5):299-304. PubMed ID: 37094
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Investigations with beta-adrenoceptor blocking drugs in healthy volunteers.
    Aellig WH.
    Acta Med Scand Suppl; 1977 Jun 12; 606():71-5. PubMed ID: 19932
    [No Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics of beta-adrenoceptor blocking agents: clinical significance of hepatic and/or renal clearance.
    Borchard U.
    Clin Physiol Biochem; 1990 Jun 12; 8 Suppl 2():28-34. PubMed ID: 1982759
    [Abstract] [Full Text] [Related]

  • 16. The effect of six beta-adrenolytics and labetalol on hepatic biotransformation studied by antipyrine test, in man.
    Adamska-Dyniewska H, Dziekański S, Pruszczyński J.
    Int J Clin Pharmacol Ther Toxicol; 1986 Jun 12; 24(6):303-7. PubMed ID: 2874117
    [Abstract] [Full Text] [Related]

  • 17. Beta-adrenoceptor blocking effects of two bopindolol metabolites in isolated guinea-pig atria.
    Brasch H, Dominiak P.
    Arzneimittelforschung; 1992 Feb 12; 42(2):97-100. PubMed ID: 1351728
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Pharmacokinetic comparison of beta-adrenoceptor blocking agents.
    Kiechel JR, Meier J.
    Clin Invest Med; 1978 Feb 12; 1(3-4):135-8. PubMed ID: 42503
    [No Abstract] [Full Text] [Related]

  • 20. [Arterial hypertension, the patient, the physician and beta-blockers].
    Safar M, Cavero I, Dallochio M, Fillastre JP, Groussin P, Rouffy J.
    Sem Hop; 1982 Oct 14; 58(37):2111-3. PubMed ID: 6129702
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.